Clinical Review 97: Syndromes of severe insulin resistance

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 9, 1998, Pages 3025-3030

  Tritos, Nicholas A ^a   Mantzoros, Christos S ^a,b  

^a JOSLIN DIABETES CENTER   (United States)

^b Division of Endocrinology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; IMMUNOSUPPRESSIVE AGENT; INSULIN; OMEGA 3 FATTY ACID; SOMATOMEDIN C;

ACANTHOSIS NIGRICANS; ACROMEGALY; DIABETES MELLITUS; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; LEPRECHAUNISM; LIPODYSTROPHY; PATHOGENESIS; PHENOTYPE; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SYNDROME;

GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; MUTATION; PHENOTYPE; RECEPTOR, INSULIN; SYNDROME; THERAPEUTICS;

EID: 0031742076     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.83.9.3025     Document Type: Review

References (37)

1. Moller DE, Flier JS. 1991 Insulin resistance: mechanisms, syndromes, and implications. N Engl J Med. 325:938-948.
2. Dunaif A, Xia J, Book CB, Schenker E, Tang Z. 1995 Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest. 96:801-810.
3. Mantzoros CS, Flier JS. 1995 Insulin resistance: the clinical spectrum. In: Mazzaferi E, ed. Advances in endocrinology and metabolism. St. Louis: Mosby-Year Book; vol 6:193-232.
4. Kahn CR, Flier JS, Bar RS, et al. 1976 The syndromes of insulin resistance and acanthosis nigricans: insulin receptor disorders in man. N Engl J Med. 294:739-745.
5. Vidal-Puig A, Moller DE. 1997 Insulin resistance: Classification, prevalence, clinical manifestations, and diagnosis. In: Azziz R, Nestler JE Dewailly D, eds. Androgen excess disorders in women. Philadelphia: Lippincott Raven; 227-236.
6. Bergman RN. 1989 Toward physiological understanding of glucose tolerance: minimal model approach. Diabetes. 38:1512-1527.
7. Bergman RN, Prager R, Volund A, Olefsky JM. 1987 Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest. 79:790-800.
8. Elahi D. 1996 In praise of the hyperglycemic clamp. A method for assessment of β-cell sensitivity and insulin resistance. Diabetes Care. 19:278-286.
9. Poretsky L. 1991 On the paradox of insulin-induced hyperandrogenism in insulin-resistant states. Endocr Rev. 12:3-13.
10. Taylor SI, Grunberger G, Marcus-Samuels B, et al. 1982 Hypoglycemia associated with antibodies to the insulin receptor. N Engl J Med. 307:1422-1426.
11. Mendenhall EN. 1950 Tumor of the pineal gland with high insulin resistance. J Indiana State Med Assoc. 43:32-36.
12. Donohue WL, Uchida I. 1954 Leprechaunism: a euphemism for a rare familial disorder. J Pediatr. 45:505-519.
13. Berardinelli W. 1954 An undiagnosed endocrinometabolic syndrome: report of 2 cases. J Clin Endocrinol Metab. 14:193-204.
14. Kobberling J, Dunningan MG. 1986 Familial partial lipodystrophy: two types of an X linked dominant syndrome, lethal in the hemizygous state. J Med Genet. 23:120-127.
15. Flier JS, Moller DE, Moses AC, et al. 1993 Insulin-mediated pseudoacromegaly: clinical and biochemical characterization of a syndrome of selective insulin resistance. J Clin Endocrinol Metab. 76:1533-1541.
16. Uotani S, Yamaguchi Y, Yokota A, et al. 1994 Molecular analysis of insulin receptor gene in Werner's syndrome. Diabetes Res Clin Pract. 26:175-176.
17. Cheatham B, Kahn CR. 1995 Insulin action and the insulin signaling network. Endocr Rev. 16:117-142.
18. Baynes KCR, Whitehead J, Krook A, O'Rahilly S. 1997 Molecular mechanisms of inherited insulin resistance. Q J Med. 90:557-562.
19. Cohen P, Harel C, Bergman R, et al. 1990 Insulin resistance and acanthosis nigricans: evidence for a postbinding defect in vivo. Metabolism. 39:1006-1011.
20. Knebel B, Kellner S, Kotzka J, et al. 1997 Defects of insulin and IGF-I action at receptor and postreceptor level in a patient with type A syndrome of insulin resistance. Biochem Biophys Res Commun. 234:626-630.
21. Taylor SI, Accili D, Cama A, et al. 1991 Mutations in the insulin receptor gene in patients with genetic syndromes of insulin resistance. In: Raizada MK, LeRoith D, eds. Molecular biology and physiology of insulin and insulin-like growth factors. New York: Plenum Press; 197-213.
22. Moller DE, Cohen O, Yamaguchi Y, et al. 1994 Prevalence of mutations of the insulin receptor gene in subjects with features of the type A syndrome of insulin resistance. Diabetes. 43:247-255.
23. Krook A, Kumar S, Laing I, Boulton AJM, Wass JAH, O'Rahilly S. 1994 Molecular scanning of the insulin receptor gene in syndromes of insulin resistance. Diabetes. 43:357-368.
24. Krook A, O'Rahilly S. 1996 Mutant receptors in syndromes of insulin resistance. In: Bailliere's clinical endocrinology and metabolism. London: Bailliere Tindall; vol 10:97-122.
25. Sbraccia P, Goodman PA, Maddux BA, et al. 1991 Production of an inhibitor of insulin receptor tyrosine kinase in fibroblasts from a patient with insulin resistance and NIDDM. Diabetes. 40:295-299.
26. Dib K, Whitehead JP, Humphreys PJ, et al. 1998 Impaired activation of phosphoinositide 3 kinase by insulin in fibroblasts from patients with severe insulin resistance and pseudoacromegaly. J Clin Invest. 101:1111-1120.
27. Vigouroux C, Khallouf E, Bourut C, et al. 1997 Genetic exclusion of 14 candidate genes in lipoatrophic diabetes using linkage analysis in 10 consanguineous families. J Clin Endocrinol Metab. 82:3438-3444.
28. Burant CF, Sreenan S, Hirano K, et al. 1997 Troglitazone action is independent of adipose tissue. J Clin Invest. 100:2900-2908.
29. Mantzoros CS, Moses AC. 1997 Treatment of severe insulin resistance. In: Azziz R, Nestler JE, Dewailly D, eds. Androgen excess disorders in women, Philadelphia. Lippincott Raven; 247-255.
30. Vestergaard H, Rossen M, Urhammer SA, Muller J, Pedersen O. 1997 Short and long-term metabolic effects of recombinant human IGI-I treatment in patients with severe insulin resistance and diabetes mellitus. Eur J Endocrinol. 136:475-482.
31. Nakae J, Kato, Murashita M, Shinohara N, Tajima T, Fujieda K. 1998 Long-term effect of recombinant human IGF-I on metabolic and growth control in a patient with leprechaunism. J Clin Endocrinol Metab. 83:542-549.
32. Stoll BA. 1997 Breast cancer: further metabolic-endocrine risk markers? Br J Cancer. 76:1652-1654.
33. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopuulos D, Adami HO. 1997 Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer. 76:1115-1118.
34. Izumino K, Sakamaki H, Ishibashi M, et al. 1997 Troglitazone ameliorates insulin resistance in patients with Werner's syndrome. J Clin Endocrinol Metab. 82:2391-2395.
35. Goldfine AB, Simonson DC, Folli F, Patti ME, Kahn CR. 1995 Metabolic effects of sodium metavanadate in humans with insulin-dependent and non-insulin-dependent diabetes mellitus: in vivo and in vitro studies. J Clin Endocrinol Metab. 80:3311-3320.
36. Krook A, Soos M, Kumar S, Siddle K, O'Rahilly S. 1996 Functional activation of mutant human insulin receptor by monoclonal antibody. Lancet. 347:1586-1590.
37. Panz VR, Wing JR, Raal FJ, Kedda MA, Joffe BI. 1997 Improved glucose tolerance after effective lipid-lowering therapy with bezafibrate in a patient with lipoatrophic diabetes mellitus: a putative role for Randle's cycle in its pathogenesis? Clin Endocrinol (Oxf). 46:365-368.